GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Short-Term Debt

TLPPF (Telix Pharmaceuticals) Short-Term Debt : $12.0 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Short-Term Debt?

Telix Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2024 was $12.0 Mil.

Telix Pharmaceuticals's quarterly Short-Term Debt increased from Dec. 2023 ($0.6 Mil) to Jun. 2024 ($2.5 Mil) and increased from Jun. 2024 ($2.5 Mil) to Dec. 2024 ($12.0 Mil).

Telix Pharmaceuticals's annual Short-Term Debt increased from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($0.6 Mil) and increased from Dec. 2023 ($0.6 Mil) to Dec. 2024 ($12.0 Mil).

Telix Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Telix Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Short-Term Debt Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.01 - 0.65 12.03

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.57 0.65 2.51 12.03

Telix Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Telix Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Short-Term Debt
Comparable Companies
ASX:MSB ASX:NEU ASX:BOT ASX:OPT ASX:CU6 ASX:PYC ASX:CUV ASX:IMM ASX:OCC ASX:IMU VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TLX:USA T3X:Germany TLX:Australia
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Website
https://www.telixpharma.com
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.